Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Toll-like receptor (TLR)-8 agonists typified by the 2-alkylthiazolo[4,5-c]quinolin-4-amine (CL075) chemotype are uniquely potent in activating adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds could be promising candidate vaccine adjuvants, especially for neonatal vaccines. Alkylthiazoloquinolines with methyl, ethyl, propyl and butyl groups at C2 displayed comparable TLR8-agonistic potencies; activity diminished precipitously in the C2-pentyl compound, and higher homologues were inactive. The C2-butyl compound was unique in possessing substantial TLR7-agonistic activity. Analogues with branched alkyl groups at C2 displayed poor tolerance of terminal steric bulk. Virtually all modifications at C8 led to abrogation of agonistic activity. Alkylation on the C4-amine was not tolerated, whereas N-acyl analogues with short acyl groups (other than acetyl) retained TLR8 agonistic activity, but were substantially less water-soluble. Immunization in rabbits with a model subunit antigen adjuvanted with the lead C2-butyl thiazoloquinoline showed enhancements of antigen-specific antibody titers.

[1]  L. Glasgow,et al.  Tilorone Hydrochloride: an Oral Interferon-Inducing Agent , 1972, Antimicrobial Agents and Chemotherapy.

[2]  S. Reed,et al.  Use of defined TLR ligands as adjuvants within human vaccines , 2011, Immunological reviews.

[3]  Sangdun Choi,et al.  Comparative Analysis of Species-Specific Ligand Recognition in Toll-Like Receptor 8 Signaling: A Hypothesis , 2011, PloS one.

[4]  Shizuo Akira,et al.  Toll-like receptors as adjuvant receptors. , 2002, Biochimica et biophysica acta.

[5]  R. Rappuoli,et al.  Vaccine adjuvants: The dream becomes real , 2008, Human vaccines.

[6]  D. Stringfellow.  Comparation Interferon-Inducing and Antiviral Properties of 2-Amino-5-Bromo-6-Methyl-4-Pyrimidinol (U-25,166), Tilorone Hydrochloride, and Polyinosinic-Polycytidylic Acid , 1977, Antimicrobial Agents and Chemotherapy.

[7]  R. Balakrishna,et al.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. , 2008, Immunology letters.

[8]  S. D. Weed,et al.  5-substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and interferon-inducing agents. , 1980, Journal of medicinal chemistry.

[9]  Salk Je.  Landmark article Aug 6, 1955: Considerations in the preparation and use of poliomyelitis virus vaccine. By Jonas E. Salk. , 1984 .

[10]  R. Balakrishna,et al.  Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives. , 2011, Journal of medicinal chemistry.

[11]  M. Gale,et al.  Immune signaling by RIG-I-like receptors. , 2011, Immunity.

[12]  S. Self,et al.  Neonatal Innate TLR-Mediated Responses Are Distinct from Those of Adults1 , 2009, The Journal of Immunology.

[13]  S. Plotkin,et al.  Vaccines: the Fourth Century , 2009, Clinical and Vaccine Immunology.

[14]  T. Nguyen,et al.  Controlling plasma protein binding: structural correlates of interactions of hydrophobic polyamine endotoxin sequestrants with human serum albumin. , 2008, Molecular pharmaceutics.

[15]  C. Janeway,et al.  Innate immune recognition and control of adaptive immune responses. , 1998, Seminars in immunology.

[16]  Nikunj M. Shukla,et al.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides. , 2012, Journal of medicinal chemistry.

[17]  Nikunj M. Shukla,et al.  Potential adjuvantic properties of innate immune stimuli , 2009, Human vaccines.

[18]  C. Janeway,et al.  Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.

[19]  Nikunj M. Shukla,et al.  Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7. , 2010, Bioorganic & medicinal chemistry letters.

[20]  F. Fitzpatrick,et al.  Comparison between circulating interferon and drug levels following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different animal species. , 1982, Journal of interferon research.

[21]  Subbalakshmi S. Malladi,et al.  Potent adjuvantic activity of a CCR1-agonistic bis-quinoline. , 2012, Bioorganic & medicinal chemistry letters.

[22]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[23]  O. Levy,et al.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. , 2006, Blood.

[24]  S. Reed,et al.  Mode of action of adjuvants: implications for vaccine safety and design. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[25]  R. Rees.  [BCG vaccination in mycobacterial infections]. , 1969, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau.

[26]  Ofer Levy,et al.  Innate immunity of the newborn: basic mechanisms and clinical correlates , 2007, Nature Reviews Immunology.

[27]  M. Bertrand,et al.  NOD-like receptors and the innate immune system: coping with danger, damage and death. , 2011, Cytokine & growth factor reviews.

[28]  Laura Zimmerman,et al.  Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. , 2011, The Journal of infectious diseases.

[29]  John P. Vasilakos,et al.  Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides , 2006, The Journal of Immunology.

[30]  S. Akira,et al.  Toll-like receptors and innate immunity. , 2006, Journal of molecular medicine.

[31]  S. Self,et al.  Ontogeny of Toll-Like Receptor Mediated Cytokine Responses of Human Blood Mononuclear Cells , 2010, PloS one.

[32]  Subbalakshmi S. Malladi,et al.  Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. , 2010, Journal of medicinal chemistry.

[33]  Nikunj M. Shukla,et al.  Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. , 2010, Journal of medicinal chemistry.

[34]  S. Buch,et al.  Selective transmission of R5-tropic HIV type 1 from dendritic cells to resting CD4+ T cells. , 2001, AIDS research and human retroviruses.

[35]  Osamu Takeuchi,et al.  Pathogen recognition by innate receptors , 2008, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[36]  O. Ramilo,et al.  Challenges in infant immunity: implications for responses to infection and vaccines , 2011, Nature Immunology.

[37]  C. Janeway,et al.  Innate immune induction of the adaptive immune response. , 1999, Cold Spring Harbor symposia on quantitative biology.

[38]  C. Shapiro-Shapin.  Pearl Kendrick, Grace Eldering, and the Pertussis Vaccine , 2010, Emerging infectious diseases.

[39]  Thomas B. Clarke,et al.  Intracellular sensors of extracellular bacteria , 2011, Immunological reviews.

[40]  H. Wagner,et al.  Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 , 2002, Nature Immunology.

[41]  C. Siegrist.  The challenges of vaccine responses in early life: selected examples. , 2007, Journal of comparative pathology.

[42]  Nikunj M. Shukla,et al.  Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. , 2011, Bioorganic & medicinal chemistry letters.

[43]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[44]  Nikunj M. Shukla,et al.  Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models , 2010, Human vaccines.

[45]  J. V. D. Berg,et al.  Transplacental transport of IgG antibodies to preterm infants: a review of the literature. , 2011, Early human development.

[46]  Nikunj M. Shukla,et al.  Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline. , 2009, Bioorganic & medicinal chemistry letters.

[47]  S. Akira,et al.  TLR2 engagement on CD8 T cells lowers the thresholdfor optimal antigen‐induced T cell activation , 2006, European journal of immunology.

[48]  R. Balakrishna,et al.  Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides. , 2011, Journal of medicinal chemistry.

[49]  C. Siegrist,et al.  Neonatal immunization: where do we stand? , 2011, Current opinion in infectious diseases.

[50]  Nikunj M. Shukla,et al.  Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines. , 2012, Journal of medicinal chemistry.

[51]  Jeffrey S. Miller,et al.  Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. , 2006, International immunology.